<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82745">
  <stage>Registered</stage>
  <submitdate>10/04/2008</submitdate>
  <approvaldate>14/04/2008</approvaldate>
  <actrnumber>ACTRN12608000195358</actrnumber>
  <trial_identification>
    <studytitle>Intra-articular Sodium Hyaluronate Injection after Arthroscopic Débridement for Osteoarthritis of the Knee: A Prospective, Randomized, Controlled Study</studytitle>
    <scientifictitle>The effects of intra-articular Sodium Hyaluronate Injection after Arthroscopic Débridement for Osteoarthritis of the Knee evaluated by pain and physical scales: A Prospective, Randomized, Controlled Study</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The treatment course consisted of a continued series of three intra-articular injections of sodium hyaluronate (Orthovisc) administered during 3 consecutive weeks starting 3-weeks postoperatively (40 patients) into the affected (arthroscopied) knee joint. The HA used in this study was Orthovisc®, (30 mg sodium hyaluronate dissolved in 2 ml physiological saline; Anika Therapeutics Inc., Woburn, MA, USA).</interventions>
    <comparator>no treatment</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the pain function subscales of the Western Ontario MacMaster (WOMAC) OA Index</outcome>
      <timepoint>24 weeks after arthroscopic debridement.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>the physical function subscales of the Western Ontario MacMaster (WOMAC) OA Index</outcome>
      <timepoint>6, 12 weeks after arthroscopic debridement.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age between 40-65 years, symptomatic primary knee OA according to American College of Rheumatology criteria with a Kellgren-Lawrence (K-L) severity grade of level II or III as determined radiographically at screening.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>	Patients who refused to provide the written informed consent for taking part in the study, agreed to follow study procedures and attend all study visits.
	Patients with previously known bleeding diathesis or coagulation disorder,
	Patients who have any form of contraindication for an arthroscopy procedure,
	Patients with known allergies against chicken or chicken products for intra-articular sodium hyaluronate injection,
	Patients with secondary arthritis, like rheumatoid arthritis or suspected to have any other form of an inflammatory arthritis,
	Patients in whom microfracture technique was used during AD,
	Patients with major frontal plane deformities,
	Patients with patellar disorder or quadriceps mechanism disorders,
	Patients with advanced level of mental handicap preventing them from fulfilling the study requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/07/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Hacettepe University</primarysponsorname>
    <primarysponsoraddress>Department of orthopaedics and Traumatology, Hacettepe University School of medicine</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Nurettin Heybeli</fundingname>
      <fundingaddress>Sadik ahmet cd Taninmislar 2000 sitesi A Blok D:2 22030 Edirne</fundingaddress>
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Arthroscopic débridement and hyaluronan injections are two different interventions to treat knee osteoarthritis. Arthroscopic débridement, although controversial, is a common practice among orthopaedic surgeons in the treatment of knee osteoarthritis. There is evidence on the potential benefits of the use of Hyaluronan for knee osteoarthritis. We aimed to assess the further potential benefits of using Hyaluronan as an adjunctive therapy after arthroscopic débridement. In addition our control group (only arthroscopy) was aimed to give information on the benefits of only arthroscopic intervention.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nurettin Heybeli</name>
      <address>Sadik Ahmet cd Taninmislar 2000 Sitesi A Blok D:2 22030 Edirne</address>
      <phone>00905322861446</phone>
      <fax>00902842353941</fax>
      <email>nurettinheybeli@trakya.edu.tr</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nurettin Heybeli</name>
      <address>Sadik Ahmet cd Taninmislar 2000 Sitesi A Blok D:2 22030 Edirne</address>
      <phone>00905322861446</phone>
      <fax>00902842353941</fax>
      <email>nurettinheybeli@trakya.edu.tr</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>